Aclarion Inc. (Nasdaq: ACON, ACONW) has secured nearly $20 million in gross proceeds since Jan. 1, 2025, which fully funds its pivotal CLARITY trial. The trial is designed to demonstrate the clinical and economic value of Nociscan in spine surgery. Ryan Bond, chief strategy officer of Broomfield-based Aclarion, said, “This milestone ensures we reach the…
Annual Membership Required
You must be a Annual member to access this content.
Already a member? Log in here